Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8769306 | 0.86 | — | — | |
| SCHEMBL15509629 | 0.76 | CHRM2 (0.37) | KDM4EGAAPOLBCHRM2CHRM4 | |
| SCHEMBL3626737 | 0.74 | KDM4E (0.38) | KDM4EGAAPOLBCHRM2CHRM4 | |
| SCHEMBL28478099 | 0.73 | — | — | |
| SCHEMBL27622395 | 0.72 | MEN1 (0.34) | — | |
| SCHEMBL2858747 | 0.70 | BRD4 (0.38) | KDM4ECA2 | |
| SCHEMBL13738187 | 0.69 | GSK3A (0.42) | KDM4EGAAPOLB | |
| SCHEMBL1974003 | 0.69 | KDM4E (0.33) | KDM4EGAAPOLBCA2 | |
| SCHEMBL558683 | 0.67 | ALDH1A1 (0.42) | GAA | |
| SCHEMBL2356063 | 0.67 | HIF1A (0.42) | KDM4EPOLBADRB1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115043818-B | Succinimidyl succinyl piperazine heptamethine cyanine salt fluorescent carrier and preparation method and application thereof | 珠海高新创展医学科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-115043818-A | Succinimide succinyl piperazine heptamethine cyanine salt fluorescent carrier and preparation method and application thereof | 珠海高新创展医学科技有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-115043818-B | Succinimidyl succinyl piperazine heptamethine cyanine salt fluorescent carrier and preparation method and application thereof | 珠海高新创展医学科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-113620863-B | Piperazine and piperidine derivatives, their synthesis and use | 内盖夫国家生物技术研究所 | 2024-04-05 | — | — | CN | disclosed |
| US-20230055614-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | NAT INST BIOTECHNOLOGY NEGEV LTD (IL) | 2023-02-23 | — | — | US | disclosed |
| CN-115043818-A | Succinimide succinyl piperazine heptamethine cyanine salt fluorescent carrier and preparation method and application thereof | 珠海高新创展医学科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-113620863-A | Novel piperazine and piperidine derivatives, their synthesis and their use | 内盖夫国家生物技术研究所 | 2021-11-09 | — | — | CN | disclosed |
| CN-108290889-B | Novel piperazine and piperidine derivatives, their synthesis and their use in inhibiting VDAC oligomerization, apoptosis and mitochondrial dysfunction | 内盖夫国家生物技术研究所 | 2021-08-10 | — | — | CN | disclosed |
| US-10946013-B2 | Methods for treating central nervous system disorders using vdac inhibitors | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2021-03-16 | — | — | US | disclosed |
| US-20210040047-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2021-02-11 | — | — | US | disclosed |
| EP-3736272-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2020-11-11 | — | — | EP | disclosed |
| US-10787423-B2 | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction | THE NATIONAL INSTITUTE FOR BIOTECHNOLGY IN THE NEGEV LTD. (IL) | 2020-09-29 | — | — | US | disclosed |
| EP-3350182-B1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | NAT INST BIOTECHNOLOGY NEGEV LTD (IL) | 2020-06-03 | — | — | EP | disclosed |
| US-20200115348-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD. (IL) | 2020-04-16 | — | — | US | disclosed |
| US-10508091-B2 | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2019-12-17 | — | — | US | disclosed |
| US-10434099-B2 | Methods for treating central nervous system disorders using VDAC inhibitors | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2019-10-08 | — | — | US | disclosed |
| US-20180118700-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2018-05-03 | — | — | US | disclosed |
| US-20180078548-A1 | Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118700-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | VDAC1, VDAC2, VDAC3 | KDM4E 3161/4885GAA 3952/4885POLB 2263/4885 |
| US-10508091-B2 | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction | VDAC1, VDAC2, AIFM1 | KDM4E 2614/4885GAA 3946/4885POLB 2118/4885 |
| US-10946013-B2 | Methods for treating central nervous system disorders using vdac inhibitors | VDAC2, VDAC3, VDAC1 | KDM4E 2573/4885GAA 2690/4885POLB 3327/4885 |
| US-20200115348-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | VDAC1, VDAC2, VDAC3 | KDM4E 3696/4885GAA 3500/4885POLB 2180/4885 |
| US-20210040047-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | VDAC1, VDAC2, VDAC3 | KDM4E 3696/4885GAA 3500/4885POLB 2180/4885 |
| US-10434099-B2 | Methods for treating central nervous system disorders using VDAC inhibitors | VDAC2, VDAC3, VDAC1 | KDM4E 2573/4885GAA 2690/4885POLB 3327/4885 |
| US-20180078548-A1 | Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors | VDAC2, VDAC3, VDAC1 | KDM4E 2573/4885GAA 2690/4885POLB 3327/4885 |
| US-20230055614-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | VDAC1, VDAC2, VDAC3 | KDM4E 3245/4885GAA 3468/4885POLB 1956/4885 |
| US-10787423-B2 | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction | VDAC1, VDAC2, VDAC3 | KDM4E 3245/4885GAA 3468/4885POLB 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.